

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

In re Application of

Application Number

Filed

07/431533

11/3/89

Group Art Unit

Examiner

Paper No. _____

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

(A) referred to in United States Patent Number 5993828, column _____

(B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____, filed _____, on page _____ of paper number _____

(C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____, filed _____ or

(D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

Shannon Hunske
Signature

Shannon Hunske

Typed or printed name

4/21/00
Date

FOR PTO USE ONLY

Approved by: _____
(Initials)

Date: _____

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. This estimate is not valid for every depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



US005993828A

United States Patent [19]
Morton

[11] Patent Number: 5,993,828
[45] Date of Patent: *Nov. 30, 1999

[54] TUMOR ASSOCIATED ANTIGEN COMPOSITIONS AND METHODS

[76] Inventor: Donald L. Morton, 24752 Malibu Rd., Malibu, Calif. 90265

[*] Notice: This patent is subject to a terminal disclaimer.

[21] Appl. No.: 08/462,570

[22] Filed: Jun. 5, 1995

Related U.S. Application Data

[63] Continuation of application No. 07/431,533, Nov. 3, 1989.

[51] Int. Cl.⁶ A61K 35/12; G01N 33/53; C07K 16/30

[52] U.S. Cl. 424/277.1; 435/7.23; 530/387.7; 530/389.7; 530/828

[58] Field of Search 530/828, 387.7, 530/389.7; 435/7.23; 424/277.1

[56] References Cited

U.S. PATENT DOCUMENTS

4,233,286	11/1980	Soothill et al.
4,348,376	9/1982	Goldeberg.
4,557,931	12/1985	Irie et al.
4,562,160	12/1985	Real et al.
4,753,884	6/1988	Kit et al. 435/235
4,806,628	2/1989	Albino et al.
4,810,781	3/1989	Hollinshead et al.
4,895,817	1/1990	Wittcr 424/89
5,030,621	7/1991	Bystryn.
5,194,384	3/1993	Bystryn.
5,427,664	6/1995	Stoev et al.
5,484,596	1/1996	Hanna et al. 424/277.1

FOREIGN PATENT DOCUMENTS

306995	of 0000	European Pat. Off. .
668350	8/1995	European Pat. Off. .
2140030	of 0000	United Kingdom .
2133146	7/1984	United Kingdom .
2188 637	10/1987	United Kingdom .

OTHER PUBLICATIONS

Bystryn et al., "Preparation and Characterization of a Polyvalent Human Melanoma Antigen Vaccine," *Journal of Biological Response Modifiers*, 5:211-224, 1986.

Dunbar et al., "Protein Analysis Using High-Resolution Two-Dimensional Polyacrylamide Gel Electrophoresis," *Methods in Enzymology*, 182:441-443, 1990.

Euhus et al., "A Murine Monoclonal Antibody to a Glycoprotein Tumor Associated Antigen in Sera and Urine of Melanoma Patients," *AACR*, Abstract No. 1566, 1988.

Euhus et al., "Demonstration and Isolation of a Glycoprotein Tumor Associated Antigen from Sera of Melanoma Patients," *Proceedings of American Society of Clinical Oncology*, Abstract No. 169, 7:44, Mar., 1988.

Euhus et al., "Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine," *Cancer Immunol. Immunother.*, 29:247-254, 1989.

Gupta et al., "Immunologic Similarity Between Tumor-Associated Antigens Detected in Urine of Melanoma Patients and Those Expressed by Melanoma Cells," *Proceedings of American Society of Clinical Oncology*, Abstract No. C-35, p. 9, Mar. 1984.

Gupta et al., "Increase in Antibody Level to a Tumor Associated Antigen in Melanoma Patients Undergoing Immunotherapy with a Tumor Cell Vaccine," *Proceedings of American Society of Clinical Oncology*, Abstract No. 979, 6:249, Mar., 1987.

Huth et al., "Purification of Antigens From Urine of a Sarcoma Patient by Affinity Chromatography," *Journal of Surgical Oncology*, 18:237-247, 1981.

Paulie et al., "Monoclonal antibodies to antigens associated with transitional cell carcinoma of the human urinary bladder," *Cancer Immunol. Immunother.*, 17:173-179, 1984.

Rote et al., "Determination of Incidence and Partial Characterization of Tumor-Associated Antigens Found in the Urine of Patients Bearing Solid Tumors," *Int. J. Cancer*, 26:203-210, 1980.

Wong et al., "Demonstration of a Well-Characterized Tumor-Associated Antigen on Melanoma Cell Surface," *Journal of Surgical Oncology*, 38:147-150, 1988.

Balch and Houghton, eds., "Melanoma vaccines," In: *Cutaneous Melanoma*, J.B. Lippincott Company, PA, 42:542-559, 1989.

Embleton et al., "Immunological monitoring in a controlled trial of immunotherapy in stage lib malignant melanoma," *Br. J. Cancer*, 37:497-504, 1978.

Euhus et al., "Association between allo-immunoreactive- and xeno-immunoreactive subunits of a glycoprotein tumor-associated antigen," *Cancer Immunol. Immunother.*, 32:214-220, 1990.

Euhus et al., "Characterization of a 90-100kDa tumor-associated antigen in the sera of melanoma patients," *Int. J. Cancer*, 45:1065-1070, 1990.

Euhus et al., "Effects of melanoma cell vaccine on levels of antibody to a tumor associated antigen in melanoma patients," *Immunology*, Proceedings of AACR, Abstract 28:349, 1987.

(List continued on next page.)

Primary Examiner—Paula F. Hutzell

Assistant Examiner—Nancy A. Johnson

Attorney, Agent, or Firm—Arnold, White & Durkee

[57] ABSTRACT

A method for inducing or enhancing in a human subject the production of antibodies reactive with the polypeptide subunit of Urinary Tumor Associated Antigen having a molecular weight of about 90 to 100 kD after reduction by β -mercaptoethanol and separation by SDS-polyacrylamide gel electrophoresis is disclosed. The method comprises administering to the subject an effective dose of a composition comprising inactivated tumor cells having Urinary Tumor Associated Antigen on the cell surface and at least one tumor associated antigen selected from the group consisting of GM-2, GD-2, Fetal Antigen and Melanoma Associated Antigen.